PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL

Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has been successful with durable remissions observed with several targeted therapeutics. Protein kinase C-β (PKC-β) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferati...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: El-Gamal, Dalia, Williams, Katie, LaFollette, Taylor D., Cannon, Matthew, Blachly, James S., Zhong, Yiming, Woyach, Jennifer A., Williams, Erich, Awan, Farrukh T., Jones, Jeffrey, Andritsos, Leslie, Maddocks, Kami, Wu, Chia-Hsien, Chen, Ching-Shih, Lehman, Amy, Zhang, Xiaoli, Lapalombella, Rosa, Byrd, John C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148770/
https://ncbi.nlm.nih.gov/pubmed/25001469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-574830
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki